Critical Comparison: Hyperfine (NASDAQ:HYPR) & CardioGenics (OTCMKTS:CGNH)

Hyperfine (NASDAQ:HYPR) and CardioGenics (OTCMKTS:CGNH) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, institutional ownership, profitability, valuation, dividends, earnings and risk.

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for Hyperfine and CardioGenics, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Hyperfine	1	2	3	0	2.33
CardioGenics	0	0	0	0	0.00

Hyperfine presently has a consensus target price of $1.78, suggesting a potential upside of 25.15%. Given Hyperfine’s stronger consensus rating and higher probable upside, equities research analysts plainly believe Hyperfine is more favorable than CardioGenics.

Profitability

This table compares Hyperfine and CardioGenics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Hyperfine	-226.88%	-98.83%	-67.09%
CardioGenics	N/A	N/A	N/A

Valuation & Earnings

This table compares Hyperfine and CardioGenics”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Hyperfine	$15.33 million	9.23	-$35.57 million	($0.41)	-3.48
CardioGenics	N/A	N/A	N/A	N/A	N/A

CardioGenics has lower revenue, but higher earnings than Hyperfine.

Insider and Institutional Ownership

15.0% of Hyperfine shares are held by institutional investors. 26.3% of Hyperfine shares are held by insiders. Comparatively, 41.4% of CardioGenics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Summary

Hyperfine beats CardioGenics on 5 of the 9 factors compared between the two stocks.

About Hyperfine

Hyperfine, Inc., a medical device company, provides magnetic resonance imaging (MRI) products in the United States. The company offers Swoop Portable MR imaging system, which offers portable brain neuroimaging; and support and technical assistance services. It serves ICU, comprehensive, and primary stroke accredited facilities through direct sales and distributors. Hyperfine, Inc. was founded in 2014 and is based in Guilford, Connecticut.

About CardioGenics

CardioGenics Holdings Inc. engages in the development and commercialization of diagnostic test products for the in vitro diagnostics testing market in the United States, Canada, Europe, and internationally. Its products include QL Care Analyzer, a portable, stand-alone, and automated point-of-care (POC) immunoassay analyzer that uses a proprietary self-metering cartridge to perform immunoassay tests at the POC; a series of immunoassay tests to identify cardiac markers in the blood at the time of a heart attack; and paramagnetic beads that are used as solid surfaces in heterogeneous immunoassay tests by clinical and research laboratories. The company was formerly known as Jag Media Holdings, Inc. and changed its name to CardioGenics Holdings Inc. in 2009. The company was founded in 1997 and is headquartered in Mississauga, Canada.